Abstract
Background: Technoshere insulin (TI), Afrezza, is a form of short-acting human insulin taken by oral inhalation with meals.
Methods: literature search (English, French, Spanish) of all human studies and pertinent animal and in-vitro studies related to technosphere insulin until September 2016 with special emphasis on its safety. Results: Compared to subcutaneous insulin aspart, TI is slightly less effective, the difference in hemoglobin A1c (HbA1c) reduction being 0.19%. Use of TI is associated with lower risk of hypoglycemia and weight gain compared with insulin aspart. Apart from hypoglycemia, cough is the most common adverse effect of TI reported by 24-33% of patients. Cough induced by TI is mostly dry, occurs within 10 minutes after inhalation and usually subsides after few weeks of use. TI is contraindicated in patients with asthma and chronic obstructive lung disease in whom it causes acute bronchospasm. TI is also not recommended in smokers. All patients starting TI need to check their pulmonary function at baseline then after 6 months, and annually thereafter. Conclusions: Overall, while TI is an attractive form of prandial insulin, its use is limited by high incidence of cough, requirement of frequent monitoring of respiratory function, and lack of long-term safety data.Keywords: Affreza, insulin, hypoglycemia, safety, technoshere, TI.
Current Drug Safety
Title:Safety of Technosphere Inhaled Insulin
Volume: 12 Issue: 1
Author(s): Nasser Mikhail
Affiliation:
Keywords: Affreza, insulin, hypoglycemia, safety, technoshere, TI.
Abstract: Background: Technoshere insulin (TI), Afrezza, is a form of short-acting human insulin taken by oral inhalation with meals.
Methods: literature search (English, French, Spanish) of all human studies and pertinent animal and in-vitro studies related to technosphere insulin until September 2016 with special emphasis on its safety. Results: Compared to subcutaneous insulin aspart, TI is slightly less effective, the difference in hemoglobin A1c (HbA1c) reduction being 0.19%. Use of TI is associated with lower risk of hypoglycemia and weight gain compared with insulin aspart. Apart from hypoglycemia, cough is the most common adverse effect of TI reported by 24-33% of patients. Cough induced by TI is mostly dry, occurs within 10 minutes after inhalation and usually subsides after few weeks of use. TI is contraindicated in patients with asthma and chronic obstructive lung disease in whom it causes acute bronchospasm. TI is also not recommended in smokers. All patients starting TI need to check their pulmonary function at baseline then after 6 months, and annually thereafter. Conclusions: Overall, while TI is an attractive form of prandial insulin, its use is limited by high incidence of cough, requirement of frequent monitoring of respiratory function, and lack of long-term safety data.Export Options
About this article
Cite this article as:
Mikhail Nasser, Safety of Technosphere Inhaled Insulin, Current Drug Safety 2017; 12 (1) . https://dx.doi.org/10.2174/1574886311666160829144240
DOI https://dx.doi.org/10.2174/1574886311666160829144240 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemokine Receptors as Specific Anti-Inflammatory Targets in Peripheral Nerves
Endocrine, Metabolic & Immune Disorders - Drug Targets Secondary Metabolites from Cissampelos, A Possible Source for New Leads with Anti-Inflammatory Activity
Current Medicinal Chemistry Non-IgE Mediated Food Allergy
Inflammation & Allergy - Drug Targets (Discontinued) Solvent-Free and Self-Catalyzed Three-Component Synthesis of Diversely Substituted Pyrazolo[1,4]thiazepinones of Potential Antitumor Activity
Current Organic Synthesis Human Endotoxemia as a Model of Systemic Inflammation
Current Medicinal Chemistry Pharmacological Targets for the Inhibition of Neurogenic Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Type 2 Diabetes and Asthma: Systematic Review of the Bidirectional Relationship
Current Diabetes Reviews Vascular Remodelling and Angiogenesis in Asthma: Morphological Aspects and Pharmacological Modulation
Inflammation & Allergy - Drug Targets (Discontinued) Probiotic Research in Australia, New Zealand and the Asia-Pacific Region
Current Pharmaceutical Design Strategies for Targeting IL-4 as a Novel Therapeutic Approach for the Treatment of Atopic Dermatitis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Hydrogen Sulfide Regulates Vascular Inflammation and its Related Signaling Pathways
Current Signal Transduction Therapy Meet Our Editor
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Non-Injection Routes for Allergen Immunotherapy: Focus on Sublingual Immunotherapy
Inflammation & Allergy - Drug Targets (Discontinued) Foreward
Current Molecular Medicine Prednisolone Effects on Urine Cross-Linked N-Telopeptides of Type I Collagen (Ntx) Diurnal Rhythms in Children
Recent Patents on Inflammation & Allergy Drug Discovery Brain-Skin Connection: Stress, Inflammation and Skin Aging
Inflammation & Allergy - Drug Targets (Discontinued) Histidine Rich Glycoprotein, an Endogenous Regulator of Macrophage and Endothelial Biology
Current Angiogenesis (Discontinued) Reproductive Toxicity of T Cells in Early Life: Abnormal Immune Development and Postnatal Diseases
Current Drug Targets Medical Management and Risk Reduction of the Cardiovascular Effects of Underwater Diving
Current Vascular Pharmacology Patent Selections
Recent Patents on Biomedical Engineering (Discontinued)